KENSEY NASH ANGIO-SEAL AND DATASCOPE VASOSEAL ARE APPROVABLE, FDA ADVISORY PANEL CONCLUDES; WARNINGS ABOUT HIGH RISK GROUPS MUST BE IN LABELING
This article was originally published in The Gray Sheet
Executive SummaryKensey Nash's Angio-Seal and Datascope's VasoSeal hemostasis devices should have warnings in labeling about the lack of clinical data supporting their safety and efficacy in high risk patients, FDA's Circulatory Systems Devices Panel recommended at its May 8 meeting in Gaithersburg, Maryland.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.